Cargando…
Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone
Immune checkpoint inhibitors highlight the importance of anticancer immunity. However, their clinical utility and safety are limited by the low response rates and adverse effects. We focused on progesterone (P4), a hormone produced by the placenta during pregnancy, because it has multiple biological...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364058/ https://www.ncbi.nlm.nih.gov/pubmed/37492571 http://dx.doi.org/10.3389/fimmu.2023.1173728 |
_version_ | 1785076772191076352 |
---|---|
author | Kametani, Yoshie Ito, Ryoji Ohshima, Shino Manabe, Yoshiyuki Ohno, Yusuke Shimizu, Tomoka Yamada, Soga Katano, Nagi Kirigaya, Daiki Ito, Keita Matsumoto, Takuya Tsuda, Banri Kashiwagi, Hirofumi Goto, Yumiko Yasuda, Atsushi Maeki, Masatoshi Tokeshi, Manabu Seki, Toshiro Fukase, Koichi Mikami, Mikio Ando, Kiyoshi Ishimoto, Hitoshi Shiina, Takashi |
author_facet | Kametani, Yoshie Ito, Ryoji Ohshima, Shino Manabe, Yoshiyuki Ohno, Yusuke Shimizu, Tomoka Yamada, Soga Katano, Nagi Kirigaya, Daiki Ito, Keita Matsumoto, Takuya Tsuda, Banri Kashiwagi, Hirofumi Goto, Yumiko Yasuda, Atsushi Maeki, Masatoshi Tokeshi, Manabu Seki, Toshiro Fukase, Koichi Mikami, Mikio Ando, Kiyoshi Ishimoto, Hitoshi Shiina, Takashi |
author_sort | Kametani, Yoshie |
collection | PubMed |
description | Immune checkpoint inhibitors highlight the importance of anticancer immunity. However, their clinical utility and safety are limited by the low response rates and adverse effects. We focused on progesterone (P4), a hormone produced by the placenta during pregnancy, because it has multiple biological activities related to anticancer and immune regulation effects. P4 has a reversible immune regulatory function distinct from that of the stress hormone cortisol, which may drive irreversible immune suppression that promotes T cell exhaustion and apoptosis in patients with cancer. Because the anticancer effect of P4 is induced at higher than physiological concentrations, we aimed to develop a new anticancer drug by encapsulating P4 in liposomes. In this study, we prepared liposome-encapsulated anti-programmed death ligand 1 (PD-L1) antibody-conjugated P4 (Lipo-anti-PD-L1-P4) and evaluated the effects on the growth of MDA-MB-231 cells, a PD-L1-expressing triple-negative breast cancer cell line, in vitro and in NOG-hIL-4-Tg mice transplanted with human peripheral blood mononuclear cells (humanized mice). Lipo-anti-PD-L1-P4 at physiological concentrations reduced T cell exhaustion and proliferation of MDA-MB-231 in vitro. Humanized mice bearing MDA-MB-231 cells expressing PD-L1 showed suppressed tumor growth and peripheral tissue inflammation. The proportion of B cells and CD4+ T cells decreased, whereas the proportion of CD8+ T cells increased in Lipo-anti-PD-L1-P4-administrated mice spleens and tumor-infiltrated lymphocytes. Our results suggested that Lipo-anti-PD-L1-P4 establishes a systemic anticancer immune environment with minimal toxicity. Thus, the use of P4 as an anticancer drug may represent a new strategy for cancer treatment. |
format | Online Article Text |
id | pubmed-10364058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103640582023-07-25 Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone Kametani, Yoshie Ito, Ryoji Ohshima, Shino Manabe, Yoshiyuki Ohno, Yusuke Shimizu, Tomoka Yamada, Soga Katano, Nagi Kirigaya, Daiki Ito, Keita Matsumoto, Takuya Tsuda, Banri Kashiwagi, Hirofumi Goto, Yumiko Yasuda, Atsushi Maeki, Masatoshi Tokeshi, Manabu Seki, Toshiro Fukase, Koichi Mikami, Mikio Ando, Kiyoshi Ishimoto, Hitoshi Shiina, Takashi Front Immunol Immunology Immune checkpoint inhibitors highlight the importance of anticancer immunity. However, their clinical utility and safety are limited by the low response rates and adverse effects. We focused on progesterone (P4), a hormone produced by the placenta during pregnancy, because it has multiple biological activities related to anticancer and immune regulation effects. P4 has a reversible immune regulatory function distinct from that of the stress hormone cortisol, which may drive irreversible immune suppression that promotes T cell exhaustion and apoptosis in patients with cancer. Because the anticancer effect of P4 is induced at higher than physiological concentrations, we aimed to develop a new anticancer drug by encapsulating P4 in liposomes. In this study, we prepared liposome-encapsulated anti-programmed death ligand 1 (PD-L1) antibody-conjugated P4 (Lipo-anti-PD-L1-P4) and evaluated the effects on the growth of MDA-MB-231 cells, a PD-L1-expressing triple-negative breast cancer cell line, in vitro and in NOG-hIL-4-Tg mice transplanted with human peripheral blood mononuclear cells (humanized mice). Lipo-anti-PD-L1-P4 at physiological concentrations reduced T cell exhaustion and proliferation of MDA-MB-231 in vitro. Humanized mice bearing MDA-MB-231 cells expressing PD-L1 showed suppressed tumor growth and peripheral tissue inflammation. The proportion of B cells and CD4+ T cells decreased, whereas the proportion of CD8+ T cells increased in Lipo-anti-PD-L1-P4-administrated mice spleens and tumor-infiltrated lymphocytes. Our results suggested that Lipo-anti-PD-L1-P4 establishes a systemic anticancer immune environment with minimal toxicity. Thus, the use of P4 as an anticancer drug may represent a new strategy for cancer treatment. Frontiers Media S.A. 2023-07-10 /pmc/articles/PMC10364058/ /pubmed/37492571 http://dx.doi.org/10.3389/fimmu.2023.1173728 Text en Copyright © 2023 Kametani, Ito, Ohshima, Manabe, Ohno, Shimizu, Yamada, Katano, Kirigaya, Ito, Matsumoto, Tsuda, Kashiwagi, Goto, Yasuda, Maeki, Tokeshi, Seki, Fukase, Mikami, Ando, Ishimoto and Shiina https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kametani, Yoshie Ito, Ryoji Ohshima, Shino Manabe, Yoshiyuki Ohno, Yusuke Shimizu, Tomoka Yamada, Soga Katano, Nagi Kirigaya, Daiki Ito, Keita Matsumoto, Takuya Tsuda, Banri Kashiwagi, Hirofumi Goto, Yumiko Yasuda, Atsushi Maeki, Masatoshi Tokeshi, Manabu Seki, Toshiro Fukase, Koichi Mikami, Mikio Ando, Kiyoshi Ishimoto, Hitoshi Shiina, Takashi Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title | Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title_full | Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title_fullStr | Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title_full_unstemmed | Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title_short | Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
title_sort | construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364058/ https://www.ncbi.nlm.nih.gov/pubmed/37492571 http://dx.doi.org/10.3389/fimmu.2023.1173728 |
work_keys_str_mv | AT kametaniyoshie constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT itoryoji constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT ohshimashino constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT manabeyoshiyuki constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT ohnoyusuke constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT shimizutomoka constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT yamadasoga constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT katanonagi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT kirigayadaiki constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT itokeita constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT matsumototakuya constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT tsudabanri constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT kashiwagihirofumi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT gotoyumiko constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT yasudaatsushi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT maekimasatoshi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT tokeshimanabu constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT sekitoshiro constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT fukasekoichi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT mikamimikio constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT andokiyoshi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT ishimotohitoshi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone AT shiinatakashi constructionofthesystemicanticancerimmuneenvironmentintumourbearinghumanizedmousebyusingliposomeencapsulatedantiprogrammeddeathligand1antibodyconjugatedprogesterone |